These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 19300395)

  • 1. Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro.
    Winczyk K; Kunert-Radek J; Gruszka A; Radek M; Ławnicka H; Pawlikowski M
    Neuro Endocrinol Lett; 2009 Mar; 30(1):107-10. PubMed ID: 19300395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo.
    Kreutzer J; Jeske I; Hofmann B; Blumcke I; Fahlbusch R; Buchfelder M; Buslei R
    Clin Neuropathol; 2009; 28(6):430-9. PubMed ID: 19919817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor.
    Emery MN; Leontiou C; Bonner SE; Merulli C; Nanzer AM; Musat M; Galloway M; Powell M; Nikookam K; Korbonits M; Grossman AB
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):389-95. PubMed ID: 16918962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone, PPAR-gamma receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro.
    Gruszka A; Kunert-Radek J; Pawlikowski M
    Neuro Endocrinol Lett; 2005 Feb; 26(1):51-4. PubMed ID: 15726020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.
    Padova H; Rubinfeld H; Hadani M; Cohen ZR; Nass D; Taylor JE; Culler MD; Shimon I
    Mol Cell Endocrinol; 2008 May; 286(1-2):214-8. PubMed ID: 18276067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
    Lin MS; Chen WC; Bai X; Wang YD
    J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease.
    Pecori Giraldi F; Scaroni C; Arvat E; Martin M; Giordano R; Albiger N; Leao AA; Picu A; Mantero F; Cavagnini F
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):219-24. PubMed ID: 16430724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor gamma in the human pituitary gland: expression and splicing pattern in adenomas versus normal pituitary.
    Occhi G; Albiger N; Berlucchi S; Gardiman M; Scanarini M; Scienza R; Fassina A; Mantero F; Scaroni C
    J Neuroendocrinol; 2007 Jul; 19(7):552-9. PubMed ID: 17561883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells.
    Huang H; Wu D; Fu J; Chen G; Chang W; Chow HC; Leung AY; Liang R
    Eur J Haematol; 2009 Sep; 83(3):191-202. PubMed ID: 19467017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of proliferation and transforming growth factor beta3 protein expression by peroxisome proliferators-activated receptor gamma ligands in human uterine leiomyoma cells.
    Zhang CH; Wen ZQ; Li JF; Li CZ; Shi M; Yang GW; Lan SM; Zhu Y; Wang F; Zhang YJ; Wang YY; Zhang H
    Chin Med J (Engl); 2008 Jan; 121(2):166-71. PubMed ID: 18272045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of peroxisome proliferator-activated receptor-gamma in human pituitary adenomas and its correlation to tumor invasiveness].
    Huang CX; Hou YH; Zhao JN; Wang YT; Li JJ; Wen L
    Ai Zheng; 2008 Jun; 27(6):590-4. PubMed ID: 18570731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
    Mansour M; Schwartz D; Judd R; Akingbemi B; Braden T; Morrison E; Dennis J; Bartol F; Hazi A; Napier I; Abdel-Mageed AB
    Int J Oncol; 2011 Feb; 38(2):537-46. PubMed ID: 21170507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
    Bastemir M; Akin F; Yaylali GF
    Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers.
    Yee LD; Williams N; Wen P; Young DC; Lester J; Johnson MV; Farrar WB; Walker MJ; Povoski SP; Suster S; Eng C
    Clin Cancer Res; 2007 Jan; 13(1):246-52. PubMed ID: 17200362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
    Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
    Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
    Lecomte J; Flament S; Salamone S; Boisbrun M; Mazerbourg S; Chapleur Y; Grillier-Vuissoz I
    Breast Cancer Res Treat; 2008 Dec; 112(3):437-51. PubMed ID: 18204896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
    Sommer M; Wolf G
    Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
    Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
    J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation.
    Kim KY; Ahn JH; Cheon HG
    Mol Pharmacol; 2007 Sep; 72(3):674-85. PubMed ID: 17535976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
    Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
    Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.